SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum
GLD 387.40+0.5%Dec 9 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: THE ANT who wrote (198031)4/9/2023 10:22:47 AM
From: Julius Wong  Read Replies (2) of 218317
 
Sarepta Therapeutics ( SRPT) shares increased more than 1% after Citi initiated coverage with a Buy recommendation, citing a compelling setup ahead of an FDA advisory committee meeting for its gene therapy candidate SRP-9001. Analyst Neena Bitritto forecasts a $30-$40/share gain in the event of a positive AdCom vote and a low double digit/share downside.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News